|
|
Article: Sunlight Research™, Releases Its Amgen EPO Patents Report.(Report)
- Article from:
- Biotech Week
- Article date:
- September 30, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sunlight Research™ - The Source for Patent Analysis (www.sunlightresearch.com) announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio (see also Biologics).
The Report analyzes the patent claims coverage of 38 US patents owned or controlled by Amgen (NASDAQ:AMGN), and explains how those patents do or do not cover the corresponding technology used in their commercial product Epogen. The technology focuses on recombinant erythropoietin, pharmaceutical compositions comprising erythropoietin, human erythropoietin gene sequences and the combination of erythropoietin with other proteins, such as stem cell factor.
...
Related newspaper, magazine, and journal articles:
|